NCT06519591 2026-02-18
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
Ruijin Hospital
Phase 2 Recruiting
Clinical Trials
27 trialsNCT06510010 2026-01-26
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT07366528 2026-01-26
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital
Phase 3 Recruiting
NCT07038629 2026-01-07
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06576921 2025-12-23
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Xijing Hospital
Phase 2 Recruiting
NCT06584227 2025-12-08
ACPC
Jinling Hospital, China
Phase 2 Recruiting
NCT07194005 2025-09-26
Remission
Fudan University
Phase 2 Recruiting
NCT07070479 2025-09-18
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06732856 2025-07-28
NEO-CLAUD
Asan Medical Center
Phase 1/2 Recruiting
NCT07025889 2025-06-18
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
Phase 1/2 Recruiting
NCT06988956 2025-05-25
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06789679 2025-01-30
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06427005 2025-01-22
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
West China Hospital
Phase 2 Recruiting
NCT06657690 2025-01-10
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Sun Yat-sen University
Phase 2 Recruiting
NCT05218889 2024-12-31
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06487429 2024-07-05
Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06451211 2024-06-11
Neo-ICEBOAT
Sun Yat-sen University
Phase 2 Recruiting
NCT06341595 2024-04-02
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05048524 2024-03-27
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Recruiting
NCT06187597 2024-03-12
EC-CRT-007
Sun Yat-sen University
Phase 2 Recruiting
NCT06061146 2023-12-26
TCRTOE
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT05687357 2023-04-19
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05813015 2023-04-14
Study of Comparing of With and Without Sequential Therapy of S-1
Zhejiang University
Phase 3 Recruiting
NCT04047953 2023-04-05
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT05769725 2023-03-15
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
RenJi Hospital
Phase 2 Recruiting
NCT03941561 2019-05-31
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）
Fudan University
Phase 3 Recruiting